Lung Cancer
Durvalumab extends survival in limited-stage small-cell lung cancer
CHICAGO — Durvalumab conferred significant survival benefits in patients with limited-stage small-cell lung cancer following standard-of-care treatment in a randomized phase 3 trial, according to findings presented at ASCO Annual Meeting.
Healio | HemOnc Today celebrates the 2024 Disruptive Innovators
CHICAGO — Healio once again welcomed the excitement of the Disruptive Innovator Awards, working with new partners and celebrating nine distinct areas of progress in oncology and hematology.
Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer
CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.
‘We have the technology’: Telehealth increases access to palliative care for cancer
CHICAGO — Early palliative care via telehealth had an equivalent impact on quality of life as in-person visits for patients with advanced non-small cell lung cancer, according to study findings presented at ASCO Annual Meeting.
Lorlatinib produces ‘unprecedented’ disease progression delay in ALK-positive lung cancer
CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.
Active cancer treatment linked to increased risk for sudden cardiac arrest
Active cancer treatment is associated with increased risk for sudden cardiac death, especially among patients younger than 74 years old and those with a history of heart failure, results from a retrospective study showed.
‘We were shocked’: Vaping considerably increases lung cancer risk among people who smoke
People who vaped and smoked cigarettes appeared four times more likely to develop lung cancer compared with those who only smoked, according to study results presented at American Association for Cancer Research Annual Meeting.
Phase 3 trial of nivolumab for advanced lung cancer misses primary endpoint
A randomized phase 3 trial that evaluated nivolumab with concurrent chemoradiotherapy for certain patients with advanced lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.
Uptake of smoking cessation support high when offered at lung cancer screening
An offer to speak with a smoking cessation practitioner during a lung cancer screening appointment was accepted by a majority of current smokers, according to results published in European Respiratory Journal.
Miniature 'tumor farm' may guide personalized lung cancer therapy
Researchers developed a miniature “tumor farm” model that uses biopsied tumor cells to enable personalized, 3-D testing of the cells’ response to various lung cancer drugs.